Close Menu

NEW YORK (360Dx) – Thermo Fisher Scientific announced after the close of the market on Monday that it has signed a definitive agreement to sell its anatomical pathology business to PHC Holdings for about $1.14 billion in cash.

Part of Thermo Fisher's Specialty Diagnostics segment, the anatomical pathology business provides microscope slides, instruments, and consumables. It has about 1,200 employees in the US, Europe, and China, and generates approximately $350 million in revenues annually.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.